Cipla has informed that the Board of the Directors of the Company at its meeting held today 29th July 2022, has approved the Unaudited Financial Results (standalone and consolidated) for the quarter ended 30th June 2022. Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company has enclosed as follows: Unaudited financial results (standalone and consolidated) as per Indian Accounting Standards for the quarter ended 30th June 2022 and Limited review report (standalone and consolidated) by Walker Chandiok & Co LLP, Statutory Auditor of the Company, for the quarter ended 30th June 2022. The meeting of the Board of Directors of the Company commenced at 12.15 pm IST and is still in progress. The end time of the meeting will be separately intimated to the Stock Exchanges on conclusion. The above-mentioned documents will also be available on the Company's website www.cipla.com in the Investor Section.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1673.30 |
| Dr. Reddys Lab | 1237.90 |
| Cipla | 1236.15 |
| Zydus Lifesciences | 938.75 |
| Lupin | 2328.70 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: